keyword
MENU ▼
Read by QxMD icon Read
search

Modified vaccinia virus ankara

keyword
https://www.readbyqxmd.com/read/28153101/viral-vector-malaria-vaccines-induce-high-level-t-cell-and-antibody-responses-in-west-african-children-and-infants
#1
Carly M Bliss, Abdoulie Drammeh, Georgina Bowyer, Guillaume S Sanou, Ya Jankey Jagne, Oumarou Ouedraogo, Nick J Edwards, Casimir Tarama, Nicolas Ouedraogo, Mireille Ouedraogo, Jainaba Njie-Jobe, Amidou Diarra, Muhammed O Afolabi, Alfred B Tiono, Jean Baptiste Yaro, Uche J Adetifa, Susanne H Hodgson, Nicholas A Anagnostou, Rachel Roberts, Christopher J A Duncan, Riccardo Cortese, Nicola K Viebig, Odile Leroy, Alison M Lawrie, Katie L Flanagan, Beate Kampmann, Egeruan B Imoukhuede, Sodiomon B Sirima, Kalifa Bojang, Adrian V S Hill, Issa Nébié, Katie J Ewer
Heterologous prime-boosting with viral vectors encoding the pre-erythrocytic antigen thrombospondin-related adhesion protein fused to a multiple epitope string (ME-TRAP) induces CD8(+) T cell-mediated immunity to malaria sporozoite challenge in European malaria-naive and Kenyan semi-immune adults. This approach has yet to be evaluated in children and infants. We assessed this vaccine strategy among 138 Gambian and Burkinabe children in four cohorts: 2- to 6-year olds in The Gambia, 5- to 17-month-olds in Burkina Faso, and 5- to 12-month-olds and 10-week-olds in The Gambia...
February 1, 2017: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/28153096/hiv-1-conserved-mosaics-delivered-by-regimens-with-integration-deficient-dc-targeting-lentiviral-vector-induce-robust-t-cells
#2
Edmund G Wee, Beatrice Ondondo, Peter Berglund, Jacob Archer, Andrew J McMichael, David Baltimore, Jan H Ter Meulen, Tomáš Hanke
To be effective against HIV type 1 (HIV-1), vaccine-induced T cells must selectively target epitopes, which are functionally conserved (present in the majority of currently circulating and reactivated HIV-1 strains) and, at the same time, beneficial (responses to which are associated with better clinical status and control of HIV-1 replication), and rapidly reach protective frequencies upon exposure to the virus. Heterologous prime-boost regimens using virally vectored vaccines are currently the most promising vaccine strategies; nevertheless, induction of robust long-term memory remains challenging...
February 1, 2017: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/28079473/protective-immunity-against-influenza-in-hla-a2-transgenic-mice-by-modified-vaccinia-virus-ankara-vectored-vaccines-containing-internal-influenza-proteins
#3
Giuseppina Di Mario, Ester Sciaraffia, Marzia Facchini, Francesco Gubinelli, Elisa Soprana, Maddalena Panigada, Valentina Bernasconi, Bruno Garulli, Antonio Siccardi, Isabella Donatelli, Maria R Castrucci
BACKGROUND: The emergence of novel strains of influenza A viruses with hemagglutinins (HAs) that are antigenically distinct from those circulating in humans, and thus have pandemic potential, pose concerns and call for the development of more broadly protective influenza vaccines. In the present study, modified vaccinia virus Ankara (MVA) encoding internal influenza antigens were evaluated for their immunogenicity and ability to protect HLA-A2.1 transgenic (AAD) mice from infection with influenza viruses...
January 12, 2017: Pathogens and Global Health
https://www.readbyqxmd.com/read/28060410/preparation-of-cell-cultures-and-vaccinia-virus-stocks
#4
Catherine A Cotter, Patricia L Earl, Linda S Wyatt, Bernard Moss
The culturing of cell lines used with vaccinia virus, both as monolayer and in suspension, is described. The preparation of chick embryo fibroblasts (CEF) is presented for use in the production of the highly attenuated and host range-restricted modified vaccinia virus Ankara (MVA) strain of vaccinia virus. Protocols for the preparation, titration, and trypsinization of vaccinia virus stocks, as well as viral DNA preparation and virus purification methods are also included. © 2017 by John Wiley & Sons, Inc.
January 5, 2017: Current Protocols in Molecular Biology
https://www.readbyqxmd.com/read/28060405/generation-of-recombinant-vaccinia-viruses
#5
Linda S Wyatt, Patricia L Earl, Bernard Moss
This unit describes how to infect cells with vaccinia virus and then transfect them with a plasmid-transfer vector or PCR fragment to generate a recombinant virus. Selection and screening methods used to isolate recombinant viruses and a method for the amplification of recombinant viruses are described. Finally, a method for live immunostaining that has been used primarily for detection of recombinant modified vaccinia virus Ankara (MVA) is presented. © 2017 by John Wiley & Sons, Inc.
January 5, 2017: Current Protocols in Molecular Biology
https://www.readbyqxmd.com/read/28057259/modified-vaccinia-virus-ankara-history-value-in-basic-research-and-current-perspectives-for-vaccine-development
#6
REVIEW
A Volz, G Sutter
Safety tested Modified Vaccinia virus Ankara (MVA) is licensed as third-generation vaccine against smallpox and serves as a potent vector system for development of new candidate vaccines against infectious diseases and cancer. Historically, MVA was developed by serial tissue culture passage in primary chicken cells of vaccinia virus strain Ankara, and clinically used to avoid the undesirable side effects of conventional smallpox vaccination. Adapted to growth in avian cells MVA lost the ability to replicate in mammalian hosts and lacks many of the genes orthopoxviruses use to conquer their host (cell) environment...
2017: Advances in Virus Research
https://www.readbyqxmd.com/read/28031267/assessment-of-the-plasmodium-falciparum-pre-erythrocytic-antigen-uis3-as-a-potential-candidate-for-a-malaria-vaccine
#7
Rhea J Longley, Benedict R Halbroth, Ahmed M Salman, Katie J Ewer, Susanne H Hodgson, Chris J Janse, Shahid M Khan, Adrian V S Hill, Alexandra J Spencer
Efforts are currently underway to improve the efficacy of sub-unit malaria vaccines through assessment of new adjuvants, vaccination platforms and antigens. In this study, we further assess the antigen P. falciparum (Pf) upregulated in infective sporozoites 3 (PfUIS3) as a vaccine candidate. PfUIS3 was expressed in the viral vectors chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) and used to immunize mice in a prime-boost regimen. We previously demonstrated that this regimen could provide partial protection against challenge with chimeric P...
December 28, 2016: Infection and Immunity
https://www.readbyqxmd.com/read/28027665/three-year-durability-of-immune-responses-induced-by-hiv-dna-and-hiv-modified-vaccinia-virus-ankara-and-effect-of-a-late-hiv-mva-boost-in-tanzanian-volunteers
#8
Agricola Joachim, Patricia J Munseri, Charlotta Nilsson, Muhammad Bakari, Said Aboud, Eligius F Lyamuya, Teghesti Tecleab, Valentina Liakina, Gabriella Scarlatti, Merlin Robb, Patricia Earl, Bernard Moss, Britta Wahren, Fred Mhalu, Guido Ferarri, Eric Sandström, Gunnel Biberfeld
We explored the duration of immune responses and the effect of a late third HIV-modified vaccinia virus Ankara (MVA) boost in HIV-DNA primed and HIV-MVA boosted Tanzanian volunteers. Twenty volunteers who had previously received three HIV-DNA and two HIV-MVA immunizations were given a third HIV-MVA immunization three years after the second HIV-MVA boost. At the time of the third HIV-MVA, 90% of the vaccinees had antibodies to HIV-1 subtype C gp140 (median titer 200) and 85% to subtype B gp160 (median titer 100)...
December 27, 2016: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/28017426/viral-vector-vaccines-protect-cockatiels-from-inflammatory-lesions-after-heterologous-parrot-bornavirus-2-challenge-infection
#9
Solveig Runge, Marita Olbert, Christiane Herden, Sara Malberg, Angela Römer-Oberdörfer, Peter Staeheli, Dennis Rubbenstroth
Avian bornaviruses are causative agents of proventricular dilatation disease (PDD), a chronic neurologic and often fatal disorder of psittacines including endangered species. To date no causative therapy or immunoprophylaxis is available. Our previous work has shown that viral vector vaccines can delay the course of homologous bornavirus challenge infections but failed to protect against PDD when persistent infection was not prevented. The goal of this study was to refine our avian bornavirus vaccination and infection model to better represent natural bornavirus infections in order to achieve full protection against a heterologous challenge infection...
December 22, 2016: Vaccine
https://www.readbyqxmd.com/read/28012777/sequential-administration-of-a-mva-based-muc1-cancer-vaccine-and-the-tlr9-ligand-litenimod-li28-improves-local-immune-defense-against-tumors
#10
Emmanuelle Schaedler, Christelle Remy-Ziller, Julie Hortelano, Nadine Kehrer, Marie-Christine Claudepierre, Tanja Gatard, Christopher Jakobs, Xavier Préville, Antoine F Carpentier, Karola Rittner
TG4010 is an immunotherapeutic vaccine based on Modified Vaccinia virus Ankara (MVA) encoding the human tumor-associated antigen MUC1 and human IL-2. In combination with first-line standard of care chemotherapy in advanced metastatic non-small-cell lung cancer (NSCLC), repeated subcutaneous injection of TG4010 improved progression-free survival in phase 2b clinical trials. In preclinical tumor models, MVATG9931, the research version of TG4010, conferred antigen-specific responses against the weak antigen human MUC1...
January 23, 2017: Vaccine
https://www.readbyqxmd.com/read/28004418/sublingual-immunization-with-japanese-encephalitis-virus-vaccines-induces-effective-immunity-through-both-cellular-and-humoral-immune-responses-in-mice
#11
Eun-Young Lee, Joo-Young Kim, Deuk-Ki Lee, Il-Sub Yoon, Hae Li Ko, Ji-Woo Chung, Jun Chang, Jae-Hwan Nam
The Japanese encephalitis virus (JEV) is the leading cause of viral encephalitis. Although there are four classes of vaccines against JEV, the immunization routes for all vaccines are subcutaneous or intramuscular injection. In here, we investigated the effectiveness of sublingual administration of the JEV live-attenuated vaccine or the recombinant modified vaccinia virus Ankara (MVA) vaccine including JEV prM/E. The mice were immunized three times intramuscularly (i.m.) or sublingually (s.l.). One week after the final immunization by both s...
December 22, 2016: Microbiology and Immunology
https://www.readbyqxmd.com/read/27997338/the-eb66%C3%A2-cell-line-as-a-valuable-cell-substrate-for-mva-based-vaccines-production
#12
Arnaud Léon, Anne-Laure David, Brice Madeline, Laurence Guianvarc'h, Elodie Dureau, Patrick Champion-Arnaud, Matthias Hebben, Thierry Huss, Benoît Chatrenet, Klaus Schwamborn
The selection of a cell substrate is a critical step for the development and manufacturing of a viral vaccine candidate. Several parameters such as cell susceptibility and permissiveness to the viral pathogens but also performance in terms of viral antigens quality and production yields are important considerations when identifying the ideal match between a viral vaccine and cell substrate. The modified vaccinia virus Ankara (MVA) is a replication-deficient viral vector that holds great promise as a vaccine platform, however only limited cell substrates have been tested or are available for industrialization...
November 21, 2016: Vaccine
https://www.readbyqxmd.com/read/27960596/heterologous-boosting-with-recombinant-vsv-846-in-bcg-primed-mice-confers-improved-protection-against-mycobacterium-infection
#13
Ming Zhang, Chunsheng Dong, Sidong Xiong
Tuberculosis (TB) remains a major health problem worldwide, and the development of effective vaccines is urgently needed. Vaccination strategies based on heterologous prime-boost protocols using Mycobacterium bovis bacillus Calmette-Guérin (BCG) as primer and modified vaccinia virus Ankara strain expressing the mycobacterial antigen Ag85A (MVA85A) as booster may increase the protective efficacy of BCG. In addition, vaccination with the recombinant viral vaccine vesicular stomatitis virus (VSV)-846 (Rv3615c, Mtb10...
December 14, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27920181/chikungunya-virus-vaccines-viral-vector-based-approaches
#14
Katrin Ramsauer, Frédéric Tangy
In 2013, a major chikungunya virus (CHIKV) epidemic reached the Americas. In the past 2 years, >1.7 million people have been infected. In light of the current epidemic, with millions of people in North and South America at risk, efforts to rapidly develop effective vaccines have increased. Here, we focus on CHIKV vaccines that use viral-vector technologies. This group of vaccine candidates shares an ability to potently induce humoral and cellular immune responses by use of highly attenuated and safe vaccine backbones...
December 15, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27876199/comparison-of-homologous-and-heterologous-prime-boost-immunizations-combining-mva-vectored-and-plant-derived-vp2-as-a-strategy-against-ibdv
#15
Matías Richetta, Evangelina Gómez, María Soledad Lucero, Silvina Chimeno Zoth, María José Gravisaco, Gabriela Calamante, Analía Berinstein
Different immunogens such as subunit, DNA or live viral-vectored vaccines against Infectious Bursal Disease virus (IBDV) have been evaluated in the last years. However, the heterologous prime-boost approach using recombinant modified vaccinia Ankara virus (rMVA), which has shown promising results in both mammals and chickens, has not been tried against this pathogen yet. IBD is a highly contagious and immunosuppressive disease of poultry that affects mainly young chicks. It is caused by IBDV, a double-stranded RNA virus carrying its main antigenic epitopes on the capsid protein VP2...
January 3, 2017: Vaccine
https://www.readbyqxmd.com/read/27830736/viral-vector-vaccines-expressing-nucleoprotein-and-phosphoprotein-genes-of-avian-bornaviruses-ameliorate-homologous-challenge-infections-in-cockatiels-and-common-canaries
#16
Marita Olbert, Angela Römer-Oberdörfer, Christiane Herden, Sara Malberg, Solveig Runge, Peter Staeheli, Dennis Rubbenstroth
Avian bornaviruses are causative agents of proventricular dilatation disease (PDD), an often fatal disease of parrots and related species (order Psittaciformes) which is widely distributed in captive psittacine populations and may affect endangered species. Here, we established a vaccination strategy employing two different well described viral vectors, namely recombinant Newcastle disease virus (NDV) and modified vaccinia virus Ankara (MVA) that were engineered to express the phosphoprotein and nucleoprotein genes of two avian bornaviruses, parrot bornavirus 4 (PaBV-4) and canary bornavirus 2 (CnBV-2)...
November 10, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27817963/a-mva-construct-expressing-a-secretable-form-of-the-dengue-virus-3-envelope-protein-protects-immunized-mice-from-dengue-induced-encephalitis
#17
Bárbara R Quinan, Alice Freitas Versiani, Flávio G da Fonseca
Dengue is no longer restricted to tropical developing countries, but is now a major global public health problem. Despite the recent license approval of the CYD-TDV vaccine in some countries, efforts to develop a more efficient vaccine against Dengue virus (DENV) continue. Herein, we evaluate the immunogenicity and level of protection of two potential vaccines against DENV based on recombinant modified vaccinia virus Ankara (rMVA). The vaccine addressing the Envelope protein from DENV serotype 3 to the endoplasmic reticulum elicited neutralizing antibodies titers which correlate with protection, and also confers protection upon challenge in a mouse model...
December 7, 2016: Vaccine
https://www.readbyqxmd.com/read/27809679/induction-of-both-local-immune-response-in-mice-and-protection-in-a-rabbit-model-by-intranasal-immunization-with-modified-vaccinia-ankara-virus-expressing-a-secreted-form-of-bovine-herpesvirus-1-glycoprotein-d
#18
María Paula Del Medico Zajac, Flavia Adriana Zanetti, María Soledad Esusy, Carlos Rodolfo Federico, Osvaldo Zabal, Alejandro Rafael Valera, Gabriela Calamante
In this study, we evaluated the immunogenicity and efficacy of mucosal delivery of a recombinant modified vaccinia Ankara virus (MVA) expressing the secreted version of bovine herpesvirus type 1 (BoHV-1) glycoprotein D (MVA-gDs) without addition of adjuvant in two animal models. First, we demonstrated the capability of MVA-gDs of inducing both local and systemic anti-gD humoral immune response after intranasal immunization of mice. Then, we confirmed that two doses of MVA-gDs administered intranasally to rabbits induced systemic anti-gD antibodies and conferred protection against BoHV-1 challenge...
January 2017: Viral Immunology
https://www.readbyqxmd.com/read/27760761/mva-vaccine-encoding-cmv-antigens-safely-induces-durable-expansion-of-cmv-specific-t-cells-in-healthy-adults
#19
Corinna La Rosa, Jeff Longmate, Joy Martinez, Qiao Zhou, Teodora I Kaltcheva, Weimin Tsai, Jennifer Drake, Mary Carroll, Felix Wussow, Flavia Chiuppesi, Nicola Hardwick, Sanjeet Dadwal, Ibrahim Aldoss, Ryotaro Nakamura, John A Zaia, Don J Diamond
Attenuated poxvirus modified vaccinia Ankara (MVA) is a useful viral-based vaccine for clinical investigation, because of its excellent safety profile and property of inducing potent immune responses against recombinant (r) antigens. We developed Triplex by constructing an rMVA encoding 3 immunodominant cytomegalovirus (CMV) antigens, which stimulates a host antiviral response: UL83 (pp65), UL123 (IE1-exon4), and UL122 (IE2-exon5). We completed the first clinical evaluation of the Triplex vaccine in 24 healthy adults, with or without immunity to CMV and vaccinia virus (previous DryVax smallpox vaccination)...
January 5, 2017: Blood
https://www.readbyqxmd.com/read/27741426/non-plaque-forming-virions-of-modified-vaccinia-virus-ankara-express-viral-genes
#20
Anna-Theresa Lülf, Astrid Freudenstein, Lisa Marr, Gerd Sutter, Asisa Volz
In cell culture infections with vaccinia virus the number of counted virus particles is substantially higher than the number of plaques obtained by titration. We found that standard vaccine preparations of recombinant Modified Vaccinia virus Ankara produce only about 20-30% plaque-forming virions in fully permissive cell cultures. To evaluate the biological activity of the non-plaque-forming particles, we generated recombinant viruses expressing fluorescent reporter proteins under transcriptional control of specific viral early and late promoters...
October 11, 2016: Virology
keyword
keyword
11297
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"